R. Nasyrova

发表

Olanzapine (OLN) versus aprepitant (APR) in patients receiving high-emetogenic chemotherapy: Final results of randomized phase II trial.

S. Tjulandin, A. Tryakin, M. Fedyanin, 2019, Journal of Clinical Oncology.

REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE

V. Gorbunova, A. Tryakin, A. Snegovoy, 2017 .